Press coverage about Alnylam Pharmaceuticals (NASDAQ:ALNY) has trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alnylam Pharmaceuticals earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.237244907734 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Hepatitis D – Symptoms, Diagnosis and Treatments (Alnylam … – Medgadget (blog) (medgadget.com)
- Alnylam poised to roll out first-of-its-kind RNA therapy, with a lot riding on the drug (bostonglobe.com)
- Stocks in Queue: Alnylam Pharmaceuticals, Inc., (NASDAQ:ALNY … – Stocks In The News (press release) (tradingnewsnow.com)
- Liver Cancer Therapeutics Market Global, regional and country-level analysis (emailwire.com)
- Liver Cancer Therapeutics Market Global regional and country-level analysis (reports.pr-inside.com)
Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) opened at 124.86 on Thursday. Alnylam Pharmaceuticals has a 12-month low of $31.38 and a 12-month high of $125.96. The stock’s market cap is $11.45 billion. The stock’s 50 day moving average is $98.08 and its 200-day moving average is $76.54.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.22) by ($0.12). The firm had revenue of $15.93 million for the quarter, compared to the consensus estimate of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The company’s revenue was up 82.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.05) EPS. Equities analysts expect that Alnylam Pharmaceuticals will post ($5.20) EPS for the current year.
Several brokerages have recently commented on ALNY. Goldman Sachs Group, Inc. (The) raised shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price objective for the company from $62.00 to $163.00 in a research note on Monday, October 2nd. Chardan Capital reissued a “buy” rating and issued a $124.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, September 25th. Jefferies Group LLC increased their price target on shares of Alnylam Pharmaceuticals from $102.00 to $130.00 and gave the stock a “buy” rating in a research note on Tuesday, September 26th. Stifel Nicolaus reissued a “hold” rating and issued a $83.00 price target (up from $56.00) on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 20th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $116.00 price target (up from $110.00) on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 20th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and fifteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $100.80.
In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 85,316 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $125.00, for a total transaction of $10,664,500.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, President Barry E. Greene sold 76,815 shares of the business’s stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total transaction of $7,681,500.00. Following the sale, the president now directly owns 165,399 shares in the company, valued at approximately $16,539,900. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by insiders.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.